CYP19A1 and breast carcinoma: In contrast, the use of a non-crossresistant aromatase inhibitor as a continuing adjuvant after 5 years of adjuvant tamoxifen reduces the incidence of recurrence and contralateral breast cancer by nearly 50% compared to no treatment (Goss et al, 2003).